Shield Therapeutics plc (LON:STX – Get Free Report) shares reached a new 52-week low on Monday . The company traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.43 ($0.02), with a volume of 705759 shares. The stock had previously closed at GBX 1.45 ($0.02).
Shield Therapeutics Price Performance
The company’s fifty day simple moving average is GBX 2.43 and its 200-day simple moving average is GBX 4.99. The stock has a market cap of £10.56 million, a P/E ratio of -11.67 and a beta of 0.84. The company has a current ratio of 2.95, a quick ratio of 2.16 and a debt-to-equity ratio of 21.30.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Recommended Stories
- Five stocks we like better than Shield Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Technologies to Challenge NAND Flash Dominance in AI
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- What is an Earnings Surprise?
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
